Clinical trials: Botulinum Toxins, Type A
Lateral Canthal Lines
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
The purpose of this study is to determine the safety and efficacy of 2 sequential doses of RT001 compared to vehicle control following applications at Baseline (Day 0) and Week 2.
- Trial name
- NCT00884234
- Testing
- Vehicle Control, RT001 (Botulinum Toxin Type A Topical Gel)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Revance Therapeutics, Inc.
Overactive Bladder
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
This study will assess the safety and efficacy of botulinum toxin Type A for the treatment of urinary incontinence overactive bladder in patients with a spinal cord injury or multiple sclerosis.
- Trial name
- NCT00439140
- Testing
- botulinum toxin Type A
- Where
- 4 sites in United States, Australia and 2 more
- Volunteers
- 41 people
- Sponsor
- Allergan
Post-Stroke Chronic Upper Limb Spasticity
Effectiveness and Safety of SMART [Spastic Muscle Palpation by Anatomic Landscape for BoNT-A (Botulinumtoxin-A) Injection to Reduce Muscle Tone] BoNT-A Therapy With Dysport® in Patients With Post-stroke Chronic Upper Limb Spasticity (ULS) in Real-life Setting.
The purpose of this study is to collect data for Dysport® SMART BoNT-A therapy usage in an office-based setting in post-stroke participants with chronic (> 6 months) focal Upper Limb Spasticity who have been under stable oral…
- Trial name
- SMART-NIS (NCT05224349)
- Where
- 31 sites in Germany
- Volunteers
- 121 people
- Sponsor
- Ipsen
Urinary Bladder, Overactive
Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity
This study will evaluate the efficacy and safety of GSK1358820 in Japanese patients with neurogenic detrusor overactivity (NDO) with urinary incontinence, whose symptoms have not been adequately managed with medications for…
- Trial name
- NCT02849418
- Testing
- GSK1358820
- Where
- 9 sites in Japan
- Volunteers
- 21 people
- Sponsor
- GlaxoSmithKline
Glabellar Rhytides, Frown Lines Between the Eyebrows
Safety and Efficacy Study of Repeat Treatment With PurTox® Botulinum Toxin Type A for Frown Lines Between the Eyebrows
The overall purpose of this study is to evaluate the safety and effectiveness of repeat treatment of an intramuscular dose of Mentor Purified Toxin for the reduction of frown lines, compared with placebo.
- Trial name
- PT-03b (NCT00752050)
- Testing
- Mentor Purified Toxin Botulinum Toxin Type A, Preservative-free Saline
- Where
- United States
- Volunteers
- 699 people
- Sponsor
- Mentor Worldwide, LLC
Cervical Dystonia
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
The aim of this study is to demonstrate the effectiveness and safety of 500 units of Dysport manufactured at a new manufacturing facility in Europe.
- Trial name
- NCT00257660
- Testing
- Botulinum toxin type A
- Where
- 22 sites in United States, Russia
- Volunteers
- 116 people
- Sponsor
- Ipsen
Crow's Feet Lines
A Phase 1/3 Clinical Trial to Evaluate the Safety and Efficacy of HUTOX Compared to Botox® in Subjects With Moderate to Severe Crow's Feet Lines
A Phase 1/3 Clinical Trial to Evaluate the Safety and Efficacy of HUTOX Compared to Botox® in Subjects With Moderate to Severe Crow's Feet Lines
- Trial name
- NCT04081402
- Testing
- HU-014, Botox Inj
- Where
- South Korea
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.
Cervical Dystonia
Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia
The aim is to demonstrate equivalent efficacy and safety in the treatment of the two most frequent forms of cervical dystonia (predominantly rotational torticollis and predominantly laterocollis) with the standard initial dose of…
- Trial name
- NCT00447772
- Testing
- Botulinum toxin type A
- Where
- 106 sites in Austria, Germany
- Volunteers
- 516 people
- Sponsor
- Ipsen
Upper Limb Spasticity
A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity
This is an open-label, multicenter, phase III clinical study to evaluate the long-term safety and efficacy of multiple treatments with recombinant botulinum toxin type A (YY001) for injection in adult upper limb spasticity
- Trial name
- NCT07478822
- Testing
- Recombinant botulinum toxin type A for injection (YY001)
- Where
- 16 sites in China
- Volunteers
- 300 people
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
Cervical Dystonia
Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia
The purpose of the protocol is to assess the long term safety of repeat treatment cycles of Dysport® 500 U using 2 mL dilution scheme for the treatment of Cervical Dystonia.
- Trial name
- NCT01753336
- Testing
- Botulinum toxin type A
- Where
- 41 sites in United States
- Volunteers
- 112 people
- Sponsor
- Ipsen
Masseter Muscle Prominence
BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence
Based on the results of the Phase 2 Study 191622-130 [NCT02010775], the current Phase 2b study is designed to further evaluate the safety and efficacy of BOTOX® for the treatment of Masseter Muscle Prominence (MMP) in adults.
- Trial name
- NCT03861936
- Testing
- OnabotulinumtoxinA, Normal saline
- Where
- 14 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Allergan
Upper Limb Spasticity After Stroke
A Prospective, Non-interventional Survey to Evaluate Injection Intervals and Treatment Modalities of Botulinum Toxin A (BoNT-A) in Adult Patients Suffering From Upper Limb Spasticity After Stroke
The purpose of the protocol is to evaluate injection intervals and treatment modalities up to 3 years follow-up of botulinum toxin A (BoNT-A) in adult patients suffering from upper limb spasticity after stroke.
- Trial name
- DECIDE (NCT01239628)
- Where
- 11 sites in Belgium
- Volunteers
- 45 people
- Sponsor
- Ipsen
Cervical Dystonia
Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition in Patients With Change From Botulinum Toxin Type A
Investigation of the clinical condition in patients with cervical dystonia by Toronto Western Spasmodic Torticollis Scale (TWSTRS)
- Trial name
- NCT02175719
- Where
- 2 sites in Japan
- Volunteers
- 150 people
- Sponsor
- Eisai Co., Ltd.
Plantar Fasciitis
Phase 2 DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
The specific aim of the study is to compare the safety and efficacy of a single administration of DaxibotulinumtoxinA for Injection versus placebo for managing plantar fasciitis.
- Trial name
- NCT03137407
- Testing
- Botulinum Toxins, Type A
- Where
- 5 sites in United States
- Volunteers
- 59 people
- Sponsor
- Revance Therapeutics, Inc.
Urinary Bladder, Overactive, Urinary Incontinence
Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence
This study will evaluate the efficacy and safety of onabotulinumtoxinA 100 U (BOTOX®), compared to placebo, when injected into the bladder using an alternative injection paradigm in reducing the number of daily urinary…
- Trial name
- LO-BOT (NCT03052764)
- Testing
- onabotulinumtoxinA
- Where
- 31 sites in United States
- Volunteers
- 120 people
- Sponsor
- Allergan
Torticollis (Spasmodic)
Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia
This is an open-label, dose-escalation study to assess the safety and preliminary efficacy of daxibotulinumtoxinA in subjects with isolated cervical dystonia (CD).
- Trial name
- NCT02706795
- Testing
- DaxibotulinumtoxinA
- Where
- 13 sites in United States
- Volunteers
- 37 people
- Sponsor
- Revance Therapeutics, Inc.
Overactive Bladder, Urinary Incontinence
A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence
A study to evaluate the efficacy and safety of BOTOX® or Solifenacin in patients with overactive bladder (OAB) and urinary incontinence.
- Trial name
- NCT01767519
- Testing
- BOTOX®, solifenacin
- Where
- 8 sites in United States, Belgium and 5 more
- Volunteers
- 356 people
- Sponsor
- Allergan
Facial Contouring
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products
A study to evaluate overall participant satisfaction of face and neck appearance after treatment with onabotulinumtoxinA, JUVÉDERM® products, KYBELLA, CoolSculpting Elite, and select SkinMedica products in a diverse population.
- Trial name
- US Harmony (NCT06783621)
- Testing
- OnabotulinumtoxinA, JUVÉDERM, CoolSculpting Elite System
- Where
- 10 sites in United States
- Volunteers
- 130 people
- Sponsor
- AbbVie
Migraine Disorders
An Open Label, Study of DaxibotulinumtoxinA for Migraine Prevention
This is a prospective, multi-center, unblinded study in patients with migraine (≥ 8 MMDs(monthly migraine days)/month) requiring preventive treatment.
- Trial name
- NCT06154070
- Testing
- DaxibotulinumtoxinA
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Ki Health Partners. LLC
Cervical Dystonia
Open Label Safety/Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) in Patients With Cervical Dystonia
Open label study to evaluate the safety and immunogenicity of MYOBLOC (Botulinum Toxin Type B) in adult patients with a clinical diagnosis of Cervical Dystonia (CD).
- Trial name
- NCT00702754
- Testing
- Botulinum Toxin Type B
- Volunteers
- 502 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC